Britain's Oxford University said today it would study whether the world's best-selling prescription medicine, adalimumab, was an effective treatment for Covid-19 patients, the latest effort to repurpose existing drugs as potential coronavirus therapies.
The AVID-CC trial will test the anti-tumour necrosis factor (anti-TNF) drug and will be aimed at treating people in the community, especially in care homes. It will enrol up to 750 patients from community care settings throughout the UK.
LEAVE A COMMENT Your email address will not be published. Required fields are marked*
WHO turns to public for monkeypox name change
First post-blockade food aid ship leaves Ukraine for Africa
Gunman detained after firing shots in Canberra airport
Albanian farmer feeds coffee to fields amid fertiliser crunch
Montenegro town reels after mass shooting
Source of the River Thames driest ever as drought nears
Hungarians rally against easing of logging rules
Drought declared in several parts of England
France battles ‘monster’ wildfire